ClinicalTrials.gg
RecruitingNCT07773155Updated Aug 19, 2026

Pain Control With Ketorolac and Nerve Block After Wrist and Hand Surgery

A Phase 4 interventional study of Toradol and Oxycodone in Surgery, Upper Extremity, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by University of Chicago · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2025, registered Aug 2026).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn about the effectiveness of different pain control options after hand and wrist surgery, specifically Ketorolac, Tylenol, and a regional nerve block. Ketorolac (Toradol) is a nonsteroidal anti-inflammatory drug (NSAID) that is similar to ibuprofen (Motrin or Advil). Tylenol (acetaminophen) is a commonly used over the counter drug. A nerve block is pain medication that is applied directly to the nerves around the surgical site before the surgery and keeps working to reduce pain in the area for several hours after the surgery. All of these medicines and procedures are approved by the Food and Drug Administration (FDA) for patient care. This study aims to understand if using these medicines in combination helps patients having hand and wrist surgery avoid the need for opioid pain medications.

Read the detailed description

Participants will be enrolled in two sequential groups:

  • The first group will be consented for a post-operative pain control regimen consisting of an intraoperative regional nerve block and 3 days of round-the-clock oral ketorolac, plus prescription strength acetaminophen as needed. These analgesic elements are standard of care for patients undergoing the procedures of interest, as an alternative to opioid use, though subjects of this study will be asked to use them as first-line therapy and receive other medications only for breakthrough pain.
  • The second group will be consented for a post-operative pain control regimen consisting of a standard care regimen of intraoperative regional nerve block and 3 days of round-the-clock opioids.

Patients in both groups will be asked to complete surveys in which they rate their pain score and describe what medications they have taken for pain.

02

Conditions studied

  • Surgery, Upper Extremity

Keywords

  • Wrist Surgery, Hand Surgery, Pain Management
03

In context

Lead sponsor

University of Chicago is the lead sponsor of 924 studies on the registry; 186 are open to participants now.

Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Undergoing upper extremity surgery performed by a hand and upper extremity orthopaedic surgeon at the University of Chicago.
  3. Undergoing procedure with regional nerve block

Exclusion criteria

Exclusion Criteria:

  1. Age less than 18 years
  2. Concomitant chronic opioid use
  3. Postoperative opioid use (surgery through POD 14) for condition other than repaired fracture
  4. Medical to ketorolac use, including pregnancy
  5. Undergoing multiple concurrent surgical procedures
  6. Unable to communicate numerical pain score
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Non-Opioid

    Regional Nerve Block + Ketorolac (Toradol) + Tylenol (acetaminophen)

    Drug: Toradol

  • Active comparator
    Opioid

    Regional Nerve Block + Oxycodone (5mg, 10 tablets) + Tylenol (acetaminophen)

    Drug: Oxycodone

Interventions

  • Regional Nerve Block + Toradol + Acetaminophen

  • Regional Nerve Block + Oxycodone + Acetaminophen

06

What researchers measure

Primary outcomes

  1. Postoperative Pain, as measured by the Numeric Pain Scale

    The numerical pain rating scale is used for rating postoperative pain. Pain scores rate from 0 to 10, with higher scores indicating more severe pain.

    Time frame: 2 days, 1 week and 2 weeks post op

Secondary outcomes

  1. Opioid requirements, measured in oral morphine equivalents

    Opioid requirements for breakthrough pain will be measured in Ketorolac (Toradol) group in Oral Morphine Equivalents (OME).

    Time frame: Through 2 weeks postop

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No current plan to share data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 19, 2026
StartActual
Mar 17, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07773155
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Mar 17, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Jennifer Wolf, MD
Contact
jwolf@bsd.uchicago.edu
773-795-3583

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketorolac Tromethamine

Start the discussion